MedTrace Logo

The Effect of Dionegest Use on the Frequency of Fibromyalgia in Endometriosis

NCT05272930 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 61

Last updated 2023-02-23

No results posted yet for this study

Summary

Endometriosis usually occurs during the reproductive period of women and poses a significant burden on quality of life and social costs. The estimated prevalence in premenopausal women is 10% in clinical studies and the frequency rises to 50% in symptomatic patients with pelvic pain and infertility. Observational studies in Europe estimated the prevalence to be 8-15 per 1000 people.

Fibromyalgia is a common musculoskeletal chronic painful condition that may be accompanied by cognitive impairment, somatic symptoms, fatigue, and psychiatric symptoms. The population frequency is given as 20-80 per 1000 people. Fibromyalgia is most often diagnosed in women aged 20-55 years; prevalence increases with age and is associated with a higher prevalence of comorbidities, including endocrine and genitourinary disorders. Co-existance of endometriosis and fibromyalgia is a special entity that has not been enlightened in detal yet.

Conditions

  • Fibromyalgia
  • Endometriosis Ovary
  • Dienogest

Interventions

DRUG

Dienogest

Assessment of fibromyalgia effects after the use of dienogest

Sponsors & Collaborators

  • Gaziosmanpasa Research and Education Hospital

    lead OTHER_GOV

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-30
Primary Completion
2022-03-15
Completion
2022-04-30
FDA Drug
Yes

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05272930 on ClinicalTrials.gov